PDUFA reauthorization, FDA reform will not hold Congress in session -- FDA's Schultz.
This article was originally published in The Tan Sheet
Executive Summary
FDA REFORM/PDUFA REAUTHORIZATION WILL NOT KEEP CONGRESS IN SESSION following passage of the appropriations bills, FDA Deputy Commissioner for Policy William Schultz warned at a Sept. 3 Food & Drug Law Institute meeting in Washington DC. "Important as [the Prescription Drug User Fee Act] is, it is not going to hold Congress in session," Schultz maintained. "There is a very good chance that legislation will pass," Schultz said, "but unfortunately there is also a very real risk that it won't."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning